Noventra Pharma – Retatrutide 32mg Self Mix
R1,580.00 Original price was: R1,580.00.R1,501.00Current price is: R1,501.00.
Noventra Pharma Retatrutide 32mg Self Mix is an advanced peptide formulation designed for metabolic and wellness-focused protocols. Commonly used in body composition and weight management routines, it may assist with appetite regulation, metabolic support, and overall wellness goals when combined with proper nutrition and exercise.
In Stock
Noventra Pharma Retatrutide 32mg Self Mix is formulated for individuals seeking advanced metabolic and wellness support through a high-quality peptide formulation. Designed in a self-mix vial format, this product is commonly incorporated into modern body composition and weight management-focused protocols.
Each vial contains:
- Retatrutide – 32mg
Retatrutide is widely recognised as a next-generation triple agonist peptide, targeting:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
This advanced multi-action approach has gained significant attention for its potential role in supporting appetite regulation, reducing cravings, metabolic wellness, and body composition goals. Retatrutide is commonly explored within advanced wellness protocols aimed at supporting sustainable weight management and active lifestyle optimisation.
Manufactured with quality and consistency in mind, Noventra Pharma Retatrutide 32mg Self Mix is designed for individuals looking to incorporate advanced wellness support into their routine.
Potential Benefits:
- May support appetite management
- Assists with metabolic and wellness-focused protocols
- May help reduce cravings and overeating
- Supports body composition and active lifestyle goals
- Advanced triple agonist peptide technology
- High-quality 32mg peptide formulation
Usage:
Use according to your selected protocol or healthcare professional’s guidance.
Storage:
Store refrigerated or according to packaging instructions. Keep away from direct sunlight and out of reach of children.



















Reviews
There are no reviews yet.